Researchers Identified New Colorectal Cancer Survival Axis
A study found that a specific signaling pathway helps colorectal cancer cells resist chemotherapy.
Updated on Oct. 2, 2026 in Cancer
Scientists have uncovered a biological signaling axis that allows colorectal cancer cells to develop resistance to oxaliplatin treatment. This mechanism, involving mitochondrial DNA, helps cancer cells survive under chemical stress.
Why it matters
Understanding this signaling axis reveals how cancer cells adapt to survive chemotherapy, potentially opening new pathways to improve treatment efficacy. Targeting these survival mechanisms could help doctors overcome acquired resistance in patients.
The study identified that TFAM loss leads to mitochondrial DNA leakage, which triggers the STING-TBK1 signaling axis to boost lysophagic flux in cancer cells.
The players
Oncogene
This is a peer-reviewed scientific journal that focuses on the molecular basis of cancer and publishes research on signaling pathways and tumor progression.
The details
Oxaliplatin treatment typically causes lysosomal damage in colorectal cancer cells, but cells adapt by activating a survival pathway fueled by mitochondrial DNA leaking into the cytosol. By inhibiting TBK1, researchers were able to reduce this lysophagic flux and restore sensitivity to the chemotherapy agent in laboratory models.
Timeline
The study was published in the journal Oncogene on October 2, 2026.
The Big Picture
This study shifts the focus of cancer treatment research toward the TFAM-mtDNA-STING-TBK1 axis as a primary target for overcoming chemotherapy resistance. By identifying this specific survival mechanism, the research bridges the gap between mitochondrial damage and cellular adaptation in oncology.
While currently limited to laboratory models, these findings may eventually inform the development of combination therapies that prevent cancer cells from developing drug resistance. Patients undergoing oxaliplatin treatment should continue following current medical protocols until further human-based trials are conducted.
The takeaway
This research provides a deeper look into the defensive mechanisms cancer cells use to survive chemotherapy treatments. Future efforts in oncology may focus on blocking these specific pathways to improve long-term outcomes for patients with treatment-resistant cancers.
Further reading
Learn more about the latest research in /health/diseases/cancer/.
Source note: This article includes information reported by Nature.
